Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Latest addition to Alcon’s intraocular lens (IOL) portfolio expands surgeons’ presbyopia-correcting IOL (PC-IOL) offerings Vivity X-WAVE technology delivers extended range of vision while...
GAMCO Investors, Inc. (NYSE:GBL) (“GAMCO”) announced today that representatives of Associated Capital Group, Inc. (NYSE:AC), its recently completed spin-off, will be commemorating the new...
Magenta Medical, Developer of Novel Heart Failure Therapy, Secures $4 Million in Seed Round from Pitango Venture Capital Magenta Medical, Developer of Novel Heart Failure Therapy, Secures $4...
The Zacks Analyst Blog Highlights: Alcon, Novartis AG, Lazard, Celgene and Elan PR Newswire CHICAGO, April 11, 2011 CHICAGO, April 11, 2011 /PRNewswire/ -- Zacks.com announces the list of stocks...
Alcon, Inc. (NYSE:ACL) announced that its shareholders approved the merger of Alcon into Novartis AG at its Annual General Meeting of Shareholders. Under the terms of the...
Alcon, Inc. (NYSE:ACL) has filed its Form 20-F annual report of foreign private issuer with the U.S. Securities and Exchange Commission (SEC). An electronic version of this...
Alcon, Inc. (NYSE:ACL) announced today that it will hold its Annual General Meeting of shareholders on April 7, 2011. The company will hold the meeting at 3:30 p.m. Central...
Zacks Releases Four Powerful 'Buy' Stocks: NVIDIA, Alcon, Rosetta Resources and Corn Products International PR Newswire CHICAGO, Feb. 24, 2011 CHICAGO, Feb. 24, 2011 /PRNewswire/ -- Four free...
Alcon, Inc. (NYSE:ACL) reported that global sales rose 5.7 percent to $1.81 billion for the fourth quarter of 2010. Revenue from acquisitions added 100 basis points to sales...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
